# K073382

# Applicant

Focus Diagnostics, Inc. 10703 Progress Way Cypress, California 90630 USA

# Establishment Registration No. 2023365

Contact Person

Constance Bridges tel 714.220.1900 fax 714.995.6921 cbridges@focusdx.com

# Summary Date

July 17, 2008

Proprietary Name Generic Name Classification Predicate Devices

Plexus EBV IgG Multi-Analyte Diagnostics   
Epstein-Barr Virus Serological Assays   
Class I   
Diamedix EBV VCA IgG ELISA   
Diamedix EBV EBNA-1 IgG ELISA   
Diamedix EBV EA-D IgG ELISA   
ATHENA MULTI-LYTE EBV IGG TEST SYSTEM   
Focus EBV-VCA ANTIBODY (IGG) - IFA

Device Description Multiplexed Immunoassay for the Qualitative Detection of Human IgG Antibodies to Epstein-Barr Virus

# Intended Use

Fcu Diagostics'PlexusEBV IgGMult-Analy Diagostics est kit sntened or qualitatively etec he preence or absence  human IgG class antibodies to viral capsid antigen (VCA), early antige-diffuse (EA-D), sBar  e of EBV infection and EBV-associated infectious mononucleosis.

The performanceof this assay has not been establishe or use in the dagnoss of nasopharyngal carcinoa and Burkihoma  estn  i patnts, r  y  point  cly r automated equipment. This assay has not been evaluated for donor screening.

# Test Principle

The Focus Diagnostics Plexus™M EBV IgG uses an Antigen Bead suspension that contains three distinct EBV antigen bead types (EA-D, VCA, & EBNA-1) and one process control bead type that fluoresce at different wavelengths and/or intensities.

The Focus Diagnostics Plexus™M EBV IgG is a three step procedure.

1. Patnt eilu n hediluse cb wint Beas.te e, then the antibodies bind to the corresponding antigen beads.   
2. Phycoerythrin-conjugated goat Anti-human IgG (Conjugate) is added, binds to the bound EBV antibody (if present), and forms a Conjugate-EBV antibody-antigen bead sandwich.   
3. Fluorescence rom each distinct EBVantigen bead typ is measured and compared against a Cutoff Calibrat.

Comparison of Plexus EBV VCA IgG analyte to Predicates:   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>PlexusTM EBV IgGMulti-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix VCA IgG,ELISA</td><td rowspan=1 colspan=1>Athena Multi-LyteEBV VCA IgG TestSystem</td><td rowspan=1 colspan=1>Focus Epstein-BarrVirus VCA IFA IgG</td></tr><tr><td rowspan=1 colspan=1>Similarities betweer</td><td rowspan=1 colspan=1>Similarities between Device and Predicate</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Focus  Diagnostics&#x27;PlexusTM EBV (VCA)IgG Multi-Analyte isintended          forqualitatively detectingthe  presence   orabsence of human IgGclass antibodies toviral capsid antigen(VCA), early antigen diffuse pattern (EA-)and nuclearantigen (EBNA-1) ofEpstein-Barr   virus(EBV) in human sera.The test is indicatedas an aid in thediagnosis of EBVinfection and EBV-associated infectiousmononucleosis.</td><td rowspan=1 colspan=1>Diamedix Corp EBVVCA IgG ELISA isintended   for thequalitative and semi-quantitativedetermination of IgGantibodies to Epstein-Barr              Virus(recombinant)   ViralCapsid Antigen (EBV-VCA IgG) in humanserum  by  indirectenzyme immunoassay.The Is-EBV-VCA IgGtest kit may be used incombination with otherEpstein-Barrserologies, Viral CapsidAntigen (VCA) IgM,Epstein-Barr NuclearAntigen-1(EBNA-1)IgG and IgM, EarlyAntigen-Diffuse (EA-IgG and IgM andheterophile antibody, asan aid in the diagnosisof           infectiousmononucleosis (IM).</td><td rowspan=1 colspan=1>The Zeus Scientific,Inc. AtheNA Multi-Lyte® EBV IgGTest System isintended for thequalitativedetection of IgGclass antibody tothree separate EBVAntigens (EBV.VCA gp-125, EBV-EA &quot;total&quot; andrecombinantEBNA-1) in humanserum using theAtheNA Multi-Lyte® System. Thetest system isintended to be usedasan aid in thelaboratorydiagnosis of EBV-associatedinfectiousmononucleosis andtoprovideepidemiologicalinformation on thedisease caused byEpstein-Barr virus.</td><td rowspan=1 colspan=1>Focus Diagnostics&#x27;Epstein-Barr VirusViral CapsidAntigens (EBVVCA)IgGImmunofluorescenceAntibody (IFA) testis intended for thedetection andsemi-quantitation ofhuman IgGantibodies to theviral capsid antigens(VCA)of Epstein-Barr virusin human serum asan aid in the clinicaldiagnosis ofinfectiousmononucleosis.</td></tr><tr><td rowspan=1 colspan=1>Indications for use</td><td rowspan=1 colspan=1>The test is indicatedas an aid in thediagnosis of EBVinfection and EBV-associated infectiousmononucleosis.</td><td rowspan=1 colspan=1>The device is indicatedfor use with patientswith the signs andsymptoms of infectiousmononucleosis.</td><td rowspan=1 colspan=1>The ZeusScientific, Inc.AtheNA Multi-Lyte EBV IgGTest Systemis intended for thequalitativedetection of IgGclass antibody tothree separateEBVAntigens (EBV.</td><td rowspan=1 colspan=1>The test is indicatedas an aid in theclinical diagnosis ofinfectiousmononucleosis.</td></tr></table>

# K073382

<table><tr><td rowspan=1 colspan=5>Page 3 of 17</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Plexus™M EBV IgGMulti-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix VCA IgG,ELISA</td><td rowspan=1 colspan=1>Athena Multi-LyteEBV VCA IgG TestSystem</td><td rowspan=1 colspan=1>Focus Epstein-BarrVirus VCA IFA IgG</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VCA, EBV-EAand EBNA-1) inhuman serumusing the AtheNAMulti-Lyte System. Thetest system isintended to beused with theseEBV IgG markersalongwith anti-EBVVCA IgM to aidin the laboratorydiagnosis ofEBV-associatedinfectiousmononucleosisand to provideepidemiologicalinformation onthe diseasescaused byEBV virus.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>ImmunoglobulinType</td><td rowspan=1 colspan=1>lgG</td><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>IgG</td></tr><tr><td rowspan=1 colspan=1>Sample matrix</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>CLIA complexity</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Difference between Device and Predicate</td><td rowspan=1 colspan=1>Difference between Device and Predicate</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>EBV-VCA: VCA gP125, affinity purifiedantigen</td><td rowspan=1 colspan=1>EBV-VCA:Recombinant 47 kDafusion half of p18</td><td rowspan=1 colspan=1>EBV VCA gp25</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>N/A- purified protein</td><td rowspan=1 colspan=1>N/A- Recombinantprotein</td><td rowspan=1 colspan=1>N/A native protein</td><td rowspan=1 colspan=1>N/A- purifiedprotein</td></tr><tr><td rowspan=1 colspan=1>Host Cell Line</td><td rowspan=1 colspan=1>EBV-VCA: Native(P3H3 orP3HR-1</td><td rowspan=1 colspan=1>EBV-VCA: E. coli(unknown)</td><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Multiplex MicrobeadImmunoassay(MMIA) based onLuminex XMAPtechnology.</td><td rowspan=1 colspan=1>Enzyme Immunoassaytechnology.</td><td rowspan=1 colspan=1>Multiplex beadimmunoassay</td><td rowspan=1 colspan=1>ImmunofluorescenceAntibody (IFA) test</td></tr></table>

# K073382

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>PlexusTM EBV IgGMulti-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix VCA IgG,ELISA</td><td rowspan=1 colspan=1>Athena Multi-LyteEBV VCA IgG TestSystem</td><td rowspan=1 colspan=1>Focus Epstein-BarrVirus VCA IFA IgG</td></tr><tr><td rowspan=1 colspan=1>Interpretation oftest results</td><td rowspan=1 colspan=1>Perform automatedcalculations usingPlexus software.</td><td rowspan=1 colspan=1>Manual calculation</td><td rowspan=1 colspan=1>AtheNA Multi-Lyteinstrument</td><td rowspan=1 colspan=1>Manual</td></tr></table>

Comparison of Plexus EBV EBNA-1 IgG analyte to Predicate:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Name</td><td colspan="1" rowspan="1">PlexusTM EBV IgG Multi-AnalyteDiagnostics</td><td colspan="1" rowspan="1">Diamedix EBNA-1 IgG ELISA</td></tr><tr><td colspan="3" rowspan="1">Similarity between Device and Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Focus Diagnostics' PlexusTM EBV (EBNA-1) IgG Multi-Analyte is intended forqualitatively detecting the presence orabsence of human IgG class antibodies toviral capsid antigen (VCA), early antigendiffuse pattern (EA-D), and nuclear antigen(EBNA-1) of Epstein-Barr virus (EBV) inhuman sera. The test is indicated as an aidin the diagnosis of EBV infection and EBV-associated infectious mononucleosis.</td><td colspan="1" rowspan="1">Diamedix Corp EBV EBNA-I IgG ELISAis intended the qualitative and semi-quantitative determination of IgG antibodiesto Epstein-Barr Virus (recombinant)Nuclear Antigen-1 (EBNA-1 IgG) in humanserum by indirect enzyme immunoassay.The Is-EBNA-1 IgG test kit may be used incombination with other Epstein-Barrserologies, viral capsid antigen (VCA) IgGand IgM, Epstein-Barr nuclear antigen-l(EBNA-1) IgM, early antigen-diffuse (EA-D) IgG and IgM and heterophile antibody,as an aid in the diagnosis of infectiousmononuclcosis (IM).</td></tr><tr><td colspan="1" rowspan="1">Indications for use</td><td colspan="1" rowspan="1">The test is indicated as an aid in thediagnosis of EBV infection and EBV-associated infectious mononucleosis.</td><td colspan="1" rowspan="1">The device is indicated for use with patientswith the signs and symptoms of infectiousmononucleosis.</td></tr><tr><td colspan="1" rowspan="1">Immunoglobulin Type</td><td colspan="1" rowspan="1">IgG</td><td colspan="1" rowspan="1">IgG</td></tr><tr><td colspan="1" rowspan="1">Sample matrix</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">CLIA complexity</td><td colspan="1" rowspan="1">High</td><td colspan="1" rowspan="1">High</td></tr><tr><td colspan="1" rowspan="1">Difference between Device and Predicate</td><td colspan="1" rowspan="1">ice and Predicate</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Strain</td><td colspan="1" rowspan="1">N/A- Recombinant protein</td><td colspan="1" rowspan="1">N/A- Recombinant protein</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="1" rowspan="1">EBV-EBNA: Recombinant EBNA-1,truncated, 35 kDa</td><td colspan="1" rowspan="1">EBV-EBNA-1: 27 kDa protein purifiednative protein (Recombinant protein)</td></tr><tr><td colspan="1" rowspan="1">Host Cell Line</td><td colspan="1" rowspan="1">EBV-EBNA: Pichia pastoris</td><td colspan="1" rowspan="1">EBV-EBNA: Native (unknown)</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Multiplex Microbead Immunoassay(MMIA) based on Luminex XMAPtechnology.</td><td colspan="1" rowspan="1">Enzyme Immunoassay technology.</td></tr><tr><td colspan="1" rowspan="1">Interpretation of testresults</td><td colspan="1" rowspan="1">Perform automated calculations using</td><td colspan="1" rowspan="1">Manual calculation</td></tr></table>

# Comparison of Plexus EBV EA-D IgG analyte to Predicate:

Comparison to Predicate

<table><tr><td rowspan=1 colspan=1>Connpason to T red</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>PlexusTM EBV IgG Multi-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix EA-D IgG ELISA</td></tr><tr><td rowspan=1 colspan=3>Similarity between Device and Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Focus Diagnostics&#x27; PlexusTM EBV (EA-D)IgG Multi-Analyte is intended forqualitatively detecting the presence orabsence of human IgG class antibodies toviral capsid antigen (VCA), early antigen -diffuse pattern (EA-D), and nuclear antigen(EBNA-1) of Epstein-Barr virus (EBV) inhuman sera. The test is indicated as an aid inthe diagnosis of EBV infection and EBV-associated infectious mononucleosis.</td><td rowspan=1 colspan=1>Diamedix Corp.EBV EA-D IgG ELISA isintended for the qualitative and semi-quantitative determination of IgG antibodiesto Epstein-Barr Virus (recombinant) EarlyAntigen Diffuse (EBV-EA-D IgG) in humanserum by indirect enzyme immunoassay. TheIs-EBV-EA-D IgG test kit may be used incombination with other Epstein-Barrserologies, Viral Capsid Antigen (VCA) IgGand IgM, Epstein-Barr Nuclear Antigen-l(EBNA-1) IgG and IgM, Early Antigen-Diffuse (EA-D) IgM and heterophileantibody, as an aid in the diagnosis ofinfectious mononucleosis (IM).</td></tr><tr><td rowspan=1 colspan=1>Indications for use</td><td rowspan=1 colspan=1>The test is indicated as an aid in the diagnosisof EBV infection and EBV-associatedinfectious mononucleosis.</td><td rowspan=1 colspan=1>The device is indicated for use with patientswith the signs and symptoms of infectiousmononucleosis.</td></tr><tr><td rowspan=1 colspan=1>ImmunoglobulinType</td><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>IgG</td></tr><tr><td rowspan=1 colspan=1>Sample matrix</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>CLIA complexity</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=3>Difference between Device and Predicate</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>EBV-EA: Recombinant EA-D</td><td rowspan=1 colspan=1>EBV-EA: Recombinant EA-D 28 kDa</td></tr></table>

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 6 of 17

Comparison to Predicate

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Plexus™M EBV IgG Multi-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix EA-D IgG ELISA</td></tr><tr><td rowspan=1 colspan=1>Host Cell Line</td><td rowspan=1 colspan=1>EBV-EA: E. coli</td><td rowspan=1 colspan=1>EBV-EA: E. coli (unknown)</td></tr><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>N/A- Recombinant protein</td><td rowspan=1 colspan=1>N/A- Recombinant protein</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Multiplex Microbead Immunoassay (MMIA)based on Luminex XMAP technology.</td><td rowspan=1 colspan=1>Enzyme Immunoassay technology.</td></tr><tr><td rowspan=1 colspan=1>Interpretation oftest results</td><td rowspan=1 colspan=1>Perform automated calculations using Plexussoftware.</td><td rowspan=1 colspan=1>Manual calculation</td></tr></table>

# EXPECTED VALUES

$( N = 7 2 3 )$   
$\cdot \uparrow$   
  
index values of $\mathtt { < 0 . 9 0 }$ are negative, $\mathtt { \ge 0 . 9 0 }$ to $\$ 120$ are equivocal and $> 1 . 1 0$ are positives.

<table><tr><td rowspan=1 colspan=4>Table 1: Observed Prevalence - EBV Plexus</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VCA IgG</td><td rowspan=1 colspan=1>EBNA-1 IgG</td><td rowspan=1 colspan=1>EA-D IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>66% (478/723)</td><td rowspan=1 colspan=1>50% (362/723)</td><td rowspan=1 colspan=1>17% (120/723)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0% (3/723)</td><td rowspan=1 colspan=1>0% (2/723)</td><td rowspan=1 colspan=1>1% (9/723)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>25% (242/723)</td><td rowspan=1 colspan=1>50% (349/723)</td><td rowspan=1 colspan=1>82% (594/723)</td></tr></table>

<table><tr><td colspan="9" rowspan="1">Table 2: EBV Plexus Results VCA IgG</td></tr><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">Gender</td><td colspan="2" rowspan="1">Positive</td><td colspan="2" rowspan="1">Equivocal</td><td colspan="2" rowspan="1">Negative</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">&lt;5</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">53.3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">46.7</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">&lt;5</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">47.2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">52.8</td><td colspan="1" rowspan="1">36</td></tr><tr><td colspan="1" rowspan="1">5-12</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">43.0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">56.0</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">5-12</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">48.4</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">51.6</td><td colspan="1" rowspan="1">95</td></tr><tr><td colspan="1" rowspan="1">13-20</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">118</td><td colspan="1" rowspan="1">70.7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">29.3</td><td colspan="1" rowspan="1">167</td></tr><tr><td colspan="1" rowspan="1">13-20</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">63.1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">36.2</td><td colspan="1" rowspan="1">130</td></tr><tr><td colspan="1" rowspan="1">21-30</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">97.4</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">38</td></tr><tr><td colspan="1" rowspan="1">21-30</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">83.3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">16.7</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">31-40</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">87.5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">12.5</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">31-40</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">92.9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">41-50</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">41-50</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">92.3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">7.7</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">51-60</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">93.8</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">←</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">51-60</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">72.7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">27.3</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">61-70</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">61-70</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">80.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">20.0</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">&gt;70</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">&gt;70</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">77.8</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">11.1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">11.1</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">478</td><td colspan="1" rowspan="1">66.1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">242</td><td colspan="1" rowspan="1">33.5</td><td colspan="1" rowspan="1">723</td></tr></table>

<table><tr><td rowspan=1 colspan=9>Table 3: EBV Plexus Results EBNA-1 IgG</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>80.0</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>33.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>28.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>72.0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>37.9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>61.1</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>50.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>49.1</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>40.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>60.0</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>71.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>28.9</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>55.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>44.4</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>93.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>78.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21.4</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>76.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23.1</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>90.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>80.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>85.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>77.8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>362</td><td rowspan=1 colspan=1>50.1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>49.7</td><td rowspan=1 colspan=1>723</td></tr></table>

# K073382

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 8 of 17

<table><tr><td rowspan=1 colspan=9>Table 4: EBV Plexus Results EA-D IgG</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>86.7</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>88.9</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>89.0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>16.2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>82.6</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>19.2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>79.2</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>76.3</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>72.2</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>31.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>85.7</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>26.3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>68.4</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>84.6</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>81.3</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>63.6</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>44.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>55.6</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>30.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>70.0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>42.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>57.1</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>16.6%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>594</td><td rowspan=1 colspan=1>82.2%</td><td rowspan=1 colspan=1>723</td></tr></table>

<table><tr><td></td><td>Age Information:</td><td></td></tr><tr><td>Summary of Female Subjects</td><td>Summary of Male Subjects</td><td></td></tr><tr><td>n</td><td>474 n</td><td>399</td></tr><tr><td>mean</td><td>20.0</td><td>18.3</td></tr><tr><td>median</td><td>mean 16.0 median</td><td></td></tr><tr><td>min</td><td>1 min</td><td>14.0</td></tr><tr><td>max</td><td>88 max</td><td>1 87</td></tr></table>

![](images/7d974d4fe94e026764a31093d02ea3971c357feb196eb95810b161103d4b907d.jpg)

# PERFORMANCE CHARACTERISTICS

# Typical Antibody Response Classification

IC the Heterophile antibody.

<table><tr><td rowspan=1 colspan=2>EBV SerologicalStatus</td><td rowspan=1 colspan=1>EBNA-1 IgG</td><td rowspan=1 colspan=1>EBV VCA IgG</td><td rowspan=1 colspan=1>EBV EA-D IgG</td><td rowspan=1 colspan=1>EBV VCA IgM</td><td rowspan=1 colspan=1>HeterophileAntibody</td></tr><tr><td rowspan=14 colspan=1>Acute</td><td rowspan=8 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=6 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>Recovering</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=2>Past Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>Indeterminant</td><td rowspan=1 colspan=5>Combinations not listed above (n =18)</td></tr></table>

# Comparison Studies

i. asA  i summarized by analyte.

# EBV VCA IgG vs Consensus Predicate: Comparison by Serological Status (Prospective Population Samples N = 723) .

T coaiblLIS ss   EBVaBNA- gG VCA IG EA- G nd VCA IgM cecalyablehip ehi

<table><tr><td rowspan=1 colspan=8>Table 4: EBV VCA IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1>cYanmaGntllowb</td></tr><tr><td rowspan=1 colspan=2>Serostatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(57/57), 95% CI:93.7-100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>33.3%(1/3), 95% CI:6.1-79.2%</td></tr><tr><td rowspan=1 colspan=1>No consensus1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97.2%(70/72), 95% CI:90.4-99.2%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>Recovering</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(1/1), 95% CI:20.7-100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>96.6%(282/292), 95% Cl:93.8-98.1%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>83.3%(5/6), 95% Cl:43.6-97%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>30%(3/10), 95% CI:10.8-60.3%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>217</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>203</td><td rowspan=1 colspan=1>93.5%(203/217), 95% CI:89.5-96.1%</td></tr><tr><td rowspan=1 colspan=1>No consensus1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98%(49/50), 95% CI:89.5-99.6%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100%(15/15),95% CI:79.6-100%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

obtained. EBV EBNA-1 vs Predicate: Comparison by Serological Status (Prospective Population Samples N = 723)

# soa50 i

T al A IgMand a crcaly vaiable hetophil apid tst or he Heophinty.

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 11 of 17

<table><tr><td rowspan=1 colspan=8>Table 5: EBV EBNA-1 IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate ELISA</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>SerologicalStatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>100%(60/60), 95% CI:94-100%</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>94.2%(65/69), 95% Cl:86-97.7%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%(3/3), 95% Cl:43.8-100%</td></tr><tr><td rowspan=3 colspan=2>Recovering</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%(1/1), 95% Cl:20.7-100%</td></tr><tr><td rowspan=3 colspan=2>PreviousInfection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>284</td><td rowspan=1 colspan=1>266</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>93.7%(266/284), 95% CI:90.2-96%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>92.9%(13/14), 95% Cl:68.5-98.7%</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>99.6%(226/227), 95% CI:97.5-99.9%</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>76.3%(29/38), 95% Cl:60.8-87%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0%(0/2), 95% CI:0-65.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>100%(27/27), 95% Cl:87.5-100%</td></tr></table>

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 12 of 17

EBV EA-D vs Predicate: Comparison by Serological Status (Prospective Population Samples N = 723) s 0 W Il AA A aly aible ehi p   Hehi

<table><tr><td rowspan=1 colspan=8>Table 6: EBV EA-D IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate ELISA</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>SerologicalStatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>93%(40/43), 95% Cl:81.4-97.6%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>76.5%(13/17), 95% CI:52.7-90.4%</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>80.4%(41/51), 95% Cl:67.5-89%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>81%(17/21), 95% Cl:60-92.3%</td></tr><tr><td rowspan=3 colspan=2>Recovering</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0%(0/1), 95% CI:0-79.3%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>96%(286/298), 95% Cl:93.1-97.7%</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>98.2%(223/227), 95% CI:95.6-99.3%</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>26.9%(7/26), 95% CI:13.7-46.1%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>6.3%(2/32), 95% Cl:1.7-20.1%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>62.2%(23/37), 95% Cl:46.1-75.9%</td></tr></table>

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 13 of 17

o 150)   
Samples were collected and tested by Mid-West investigator $( n = 1 5 0 )$ .

T cy vabeELISA ss r he EBV nal EBNA- IgG,VCA IG, EA-D IgG nd VCA IgM commercially available heterophile rapid test for the Heterophile antibody.

<table><tr><td rowspan=1 colspan=8>Table 7: EBV VCA IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Serostatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>93.4%(99/106), 95% Cl:87-96.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(8/8), 95% CI:67.6-100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(1/1), 95% CI:20.7-100%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%(0/1), 95% CI:0-79.3%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>93.9%(31/33), 95% CI:80.4-98.3%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Noconsensus&#x27;</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

obtained.

A-reiaCoon  Serolgical StauRet escu pui Smple= 50 Samples were collected and tested by Mid-West investigator (n=150).

samples for EBNA-1 $| { \mathfrak { g } } { \mathfrak { G } }$ analyte when a commercial ELISA test is used as a predicate for EBNA-1 IgG analysis. Serological status a VCA IgM and a commercially available heterophile rapid test for the Heterophile antibody.

<table><tr><td rowspan=1 colspan=8>Table 8: EBV EBNA-1 IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate ELISA</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1>Y</td></tr><tr><td rowspan=1 colspan=2>Serologicaltatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>99.1%(105/106), 95% Cl:94.8-99.8%</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0%(0/4), 95% CI:0-49%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>100%(4/4), 95% Cl:51-100%</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%(2/2), 95% Cl:34.2-100%</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0%(0/8), 95% CI:0-32.4%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0%(0/4), 95% CI:0-49.0%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>100%(26/26), 95% Cl:87.1-100%</td></tr></table>

510(k) Summary of Safety and Effectiveness Plexus EBV IgG Multi-Analyte Diagnostics Catalog No. MP0500G Prepared Date: July 17, 2008 Page 15 of 17

A- Preica oprison y Seroloial Statu Retetiv resAcu uati Samples= 150 Samples were collected and tested by Mid-West investigator $( n = 1 5 0 )$ .

Ial AA IgM and a commercially available heterophile rapid test for the Heterophile antibody.

<table><tr><td rowspan=1 colspan=8>Table 9: EBV EA-D IgG Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate ELISA</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1>Y</td></tr><tr><td rowspan=1 colspan=2>SerologicalStatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>93.4%(57/61), 95% Cl:84.3-97.4%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>77.8%(35/45), 95% CI:63.7-87.5%</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(3/3), 95% CI:43.8-100%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80%(4/5), 95% Cl:37.6-96.4%</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%(2/2), 95% CI:34.2-100%</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>66.7%(8/12), 95% Cl:39.1-86.2%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0%(0/14), 95% Cl:0-21.5%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>40.9%(9/22), 95% CI:23.3-61.3%</td></tr></table>

# Inter-laboratory, Intra-assay and Inter-assay Reproducibility

below.

<table><tr><td rowspan=1 colspan=18>Table 16: Inter-laboratory, Intra-assay and Inter-assay Reproducibility</td></tr><tr><td rowspan=1 colspan=6>Plexus VCA IgG</td><td rowspan=1 colspan=6>Plexus EBNA IgG</td><td rowspan=1 colspan=6>Plexus EA IgG</td></tr><tr><td rowspan=2 colspan=1>ID</td><td rowspan=1 colspan=3>Intra-assay &amp; Inter-assay%CV</td><td rowspan=1 colspan=2>Inter-Lab</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=3>Intra-assay &amp; Inter-assay%CV</td><td rowspan=1 colspan=2>Inter-Lab</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=3>Intra-assay &amp; Inter-assay%CV</td><td rowspan=1 colspan=2>Inter-Lab</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay</td><td rowspan=1 colspan=1>Inter-assay</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay</td><td rowspan=1 colspan=1>Inter-assay</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay</td><td rowspan=1 colspan=1>Inter-assay</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.38</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>5.38</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>6.66</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>6.66</td><td rowspan=1 colspan=1>8.9%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>5.12</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>10.0%</td><td rowspan=1 colspan=1>5.12</td><td rowspan=1 colspan=1>10.1%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4.41</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>19.9%</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5.02</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>8.4%</td><td rowspan=1 colspan=1>5.03</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3.66</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>3.66</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.21</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>4.20</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.68</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>18.3%</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>15.6%</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>15.7%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.37</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>16.6%</td><td rowspan=1 colspan=1>3.37</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2.05</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>2.05</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>2.21</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>28.4%</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>27.0%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>11.8%</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>11.7%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>12.6%</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>5.6%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>13.4%</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>13.6%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>8.5%</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>13.3%</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>11.9%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>16.0%</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>11.9%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>77.0%</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>31.1%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>59.1%</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>50.9%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>33.8%</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>19.6%</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>13.4%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>11.1%</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>8.9%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>61.9%</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>12.4%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>18.2%</td><td rowspan=1 colspan=1>69.2%</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>59.3%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>9.8%</td><td rowspan=1 colspan=1>304.1%</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>134%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>64.6%</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>10.1%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>15.2%</td><td rowspan=1 colspan=1>117.9%</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>72.5%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>23.8%</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>19.8%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>106.1%</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>27.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>11.4%</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>14.0%</td><td rowspan=1 colspan=1>41.1%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>34.7%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>96.5%</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>16.9%</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>4.69</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>4.69</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>1t</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>11.2%</td><td rowspan=1 colspan=1>32.9%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>23.1%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>40.1%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>28.1%</td></tr></table>

# Inter-Lot Reproducibility

the study are summarized in the table below.   

<table><tr><td rowspan=1 colspan=9>Table 10: Inter-lot Reproducibility</td></tr><tr><td rowspan=1 colspan=3>Plexus VCA IgG</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Plexus EBNA IgG</td><td rowspan=1 colspan=3>Plexus EA-D IgG</td></tr><tr><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6.00</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>7.35</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>4.51</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>5.88</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4.76</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.86</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5.57</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4.01</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5.08</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>9.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.66</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2.39</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>4.6%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.61</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>7.2%</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2.08</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>8.6%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>14.4%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>10.8%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>30.0%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>6.4%</td></tr></table>

# Cross-Reactivity

factors interfere with test results when tested with the Plexus EBV IgG kit. A panel of $( A N \ A = 2 8$ , $C M V = 3 1$ , HSV- $\uparrow = 2 9$ , $H S V - 2 = 1 3$ . $H S V - 6 = 4$ , Rubeola Virus $= 1$ , Mumps $= 1$ , Rubella Virus $\scriptstyle = 3 9$ ,Toxoplasma gondii $= 1 9$ , and $V Z A = 3 5$ ) samples for each cross reactant $1 9 5$ analyte. Of the 107 samples tested, 41 were prescreened for EBV $| { \mathfrak { g } } { \mathfrak { G } }$ negativity. Because of the high prevalence of EBV IgG antibodies in IgG antibodies rather than cross reactivity with a potentially interfering factor.

<table><tr><td rowspan=1 colspan=12>Table 11: Cross-Reactivity</td></tr><tr><td rowspan=2 colspan=1>Cross Reactives</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Method</td><td rowspan=1 colspan=3>EBV VCA IgG</td><td rowspan=1 colspan=3>EBV EBNA IgG</td><td rowspan=1 colspan=3>EBV EAD IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>ANA.</td><td rowspan=3 colspan=1>28</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>1</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>6r5}$</td></tr><tr><td rowspan=3 colspan=1>Cytomegalovirus(CMV)</td><td rowspan=3 colspan=1>31</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>21</td><td rowspan=1 colspan=2>1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>2$</td></tr><tr><td rowspan=3 colspan=1>HSV-1</td><td rowspan=3 colspan=1>29</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>21</td><td rowspan=1 colspan=3>21</td><td rowspan=1 colspan=3>11</td></tr><tr><td rowspan=3 colspan=1>HSV-2</td><td rowspan=3 colspan=1>13</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>1</td><td rowspan=1 colspan=3>$4}$</td></tr><tr><td rowspan=3 colspan=1>HHV-6</td><td rowspan=3 colspan=1>4</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=3 colspan=1>Measles(Rubeola)</td><td rowspan=3 colspan=1>1</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td></tr></table>

# K073382

<table><tr><td rowspan=1 colspan=13>Table 11: Cross-Reactivity</td></tr><tr><td rowspan=2 colspan=1>Cross Reactives</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Method</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>EBV VCA IgG</td><td rowspan=1 colspan=3>EBV EBNA IgG</td><td rowspan=1 colspan=3>EBV EAD IgG</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>Mumps</td><td rowspan=3 colspan=1>1</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=4>0</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=3 colspan=1>Rubella Virus</td><td rowspan=3 colspan=1>39</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=2>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=2>26</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=4>81</td><td rowspan=1 colspan=3>21</td><td rowspan=1 colspan=3>1</td></tr><tr><td rowspan=3 colspan=1>Toxoplasmagondii</td><td rowspan=3 colspan=1>19</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=2>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=2>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=4>2</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>44</td></tr><tr><td rowspan=3 colspan=1>Varicella-zoster(VZV)</td><td rowspan=3 colspan=1>35</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=2>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=2>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=4>4</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>4$</td></tr></table>

S a

# Sample Storage and Handling

F negative sample.

# Interference

sample.

Focus Diagnostics, Inc. C/O Constance Bridges 10703 Progress Way Cypress, California 90630

Re: k073382 Trade/Device Name: Plexus EBV IgG Multi-Analyte Diagnostics Regulation Number: 21 CFR 866.3235 Regulation Name: Epstein-Barr Virus Serological Device Regulatory Class: Class I Product Code: LSE Dated: November 30, 2007 Received: Dccember 3, 2007

Dear Ms. Bridges:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/a0e41ec3056d5179268f675f3868b59272b5c567b7312ef93cb67378cd0ead1e.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

510(k) Number (if known): Kò 7332

Device Name:

# Plexus EBV IgG Multi-Analyte Diagnostics

Indications for Use:

Focus Diagnostics' PlexusTM EBV IgG Multi-Analyte Diagnostics test kit is intended for qualitatively detecting the presence or absence of human IgG class antibodies to viral capsid antigen (VCA), early antigen- diffuse (EA-D), and nuclear antigen (EBNA-1) of Epstein-Barr virus in human sera. The test is indicated as an aid in the diagnosis of EBV infection and EBV-associated infectious mononucleosis.

The performance of this assay has not been established for use in the diagnosis of nasopharyngeal carcinoma and Burkitt's lymphoma, for testing of immunocompromised patients, for use by a point of care facility or for use with automated equipment. This assay has not been evaluated for donor screening.